Aadi Bioscience Q2 2024 GAAP EPS $(0.54) Beats $(0.69) Estimate, Sales $6.179M Miss $6.197M Estimate. Cash And Equivalents $78.6M
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience (NASDAQ:AADI) reported Q2 2024 GAAP EPS of $(0.54), beating the $(0.69) estimate, but missed sales estimates with $6.179M. Cash and equivalents stand at $78.6M.
August 07, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aadi Bioscience reported better-than-expected Q2 2024 GAAP EPS of $(0.54), beating the $(0.69) estimate. However, sales of $6.179M missed the $6.197M estimate. Cash and equivalents are $78.6M.
The better-than-expected EPS is a positive indicator and may boost investor confidence, leading to a potential short-term price increase. The slight miss in sales is not significant enough to offset the positive EPS surprise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100